Becton Dickinson and : United States and Indonesia Expand Collaboration to End Tuberculosis
June 27, 2019 at 05:45 pm EDT
Share
JAKARTA (June 27, 2019) - Today, the United States Government through the United States Agency for International Development (USAID) and BD (Becton, Dickinson and Company), a U.S.-based global medical technology company, formalized a new partnership to support Indonesia in eliminating tuberculosis (TB) through its National Tuberculosis Program.
Today, the United States Government through the United States Agency for International Development (USAID) and BD (Becton, Dickinson and Company), a U.S.-based global medical technology company, formalized a new partnership to support Indonesia in eliminating tuberculosis (TB) through its National Tuberculosis Program.
'Fighting TB with our Indonesian partners is one of our top priorities. Our new approach, the USAID Global Accelerator to End TB, catalyzes investment from private sector partners like BD so that countries around the world, including Indonesia, can stop the spread of TB-- to benefit all people, regardless of nationality,' said USAID Mission Director Erin E. McKee.
Renuka Gadde, Vice President of BD Global Health, said: 'With this partnership, BD is able to bring its advanced capabilities and expertise in phenotypic testing to a population that needs it most. We see an opportunity to strengthen the lab eco system in terms of quality assurance, specimen referral processes and establishing systems for data capture. We look forward to a meaningful partnership with USAID Indonesia and the National TB Program of Indonesia as we collectively address the challenges associated with multi-drug resistant infections.'
Complementary to the National Tuberculosis Program, the BD and USAID partnership advances Indonesia's self-reliance in TB detection and treatment by leveraging the private sector's expertise and commitment to sustainable, effective TB solutions. This is just one of the U.S. Embassy's health sector initiatives in Indonesia, which demonstrates the breadth of engagement under the U.S.-Indonesia Strategic Partnership.
Attachments
Original document
Permalink
Disclaimer
BD - Becton, Dickinson and Company published this content on 27 June 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 June 2019 21:44:11 UTC
Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows:
- medical equipment (73.5%): surgical instruments, urological care products, pharmaceutical systems, etc.;
- diagnostic materials (18.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, etc.;
- clinical research and development tools (7.8%): tools for discovering drugs and vaccines, studying genes, culturing cells, and manipulating liquids, instruments for sorting and analyzing cells, monoclonal antibodies, etc.
Net sales are distributed geographically as follows: the United States (57.4%), Europe/Middle East/Africa (21.9%), Asia (15%) and other (5.7%).
BECTON, DICKINSON AND COMPANY 
